skip to Main Content

About PILA PHARMA

PILA PHARMA is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden.
The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.

XEN-D0501 is a synthetic small molecule that was in-licensed in 2016.
Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups.

PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes.

Further, PP-CT02, demonstrated that XEN-D0501 (administered as 4 mg BID for 28 days) – with statistical significance versus placebo – enhance the endogenous insulin response to oral glucose.

FÅ PRESSMEDDELANDEN / GET PRESS RELEASES

PilaPharma

News

Pila Pharma Press releases
KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB
Läs pressmeddelandet (in Swedish) här
(09-May-2022)

Our friends at BIOSTOCK caught our CEO Dorte X. Gram for some comments regarding our good Q1 results and our Orphan Drug Designation request!

Have a read in both English and Swedish 😃

(06-May-2022)

Late last week Redeye had a brief interview with our CEO, Dorte X. Gram regarding the last quarterly report and recent significant changes and developments in Pila.

Please, find the link to the video (in English) here

(03-May-2022)

Delårsrapport 1 januari – 31 mars 2022
Läs rapporten PDF (in Swedish) här

(26-April-2022)
Pila Pharma Press releases
Pila Pharma delårsrapport för 1 januari – 31 mars 2022
Läs pressmeddelandet (in Swedish) här

 

PILA PHARMA publishes interim report January 1 – March 31, 2022
Read the press release (in English) here

(26-April-2022)
Pila Pharma Press releases

Pila Pharma AB tillkännager certifiering av API
Läs pressmeddelandet (in Swedish) här

 

Pila Pharma AB announces certification of API
Read the press release (in English) here

(25-April-2022)
Pila Pharma Press releases

Pila Pharma bygger pipeline – ansöker om Orphan Drug Designation i USA
Läs pressmeddelandet (in Swedish) här

 

Pila Pharma builds pipeline – applies for Orphan Drug Designation in the USA
Read the press release (in English) here

(22-April-2022)
Malmö-Näringslivsgala
We’re really proud that Malmö stad has selected us as finalist in the Life Science category for the Malmö Business Price Award 2022.
Here, our CEO Dorte X. Gram first found high-risk-investors who dared thinking big and PILA PHARMA was kicked off to provide a future better treatment of diabetes!


Läs (in Swedish) här

(05-April-2022)

Årsredovisning för 2021
Läs rapporten PDF (in Swedish) här

(23-March-2022)
Pila Pharma Press releases
Pila Pharma AB publicerar årsredovisning för 2021
Läs pressmeddelandet (in Swedish) här

 

Pila Pharma AB publishes annual report for 2021
Read the press release (in English) here

(23-March-2022)
Making progress and keeping steady!
The recording of our CEO Dorte X. Gram’s presentation (in Swedish) from Aktiespararna is now live.
Please, find the link to the video (in Swedish) here
(15-March-2022)
Our CEO Dorte X. Gram presented our status yesterday evening including the progress with more FTE’s and API in the making
Please, find the link to the video (in English) here
(05-March-2022)
We’re very honoured that PILA PHARMA is a final nominee for the 2022 Malmö Business Award within Life Science!
(04-March-2022)
Good summary of our progress as reported in our quarterly report plus comments from our CEO Dorte X. Gram
 
Vänligen läs artikeln (in Swedish) här


Please, read the article (in English) here

(03-March-2022)
We’re pleased to share this quarterly report interview with our CEO Dorte X. Gram, on our good progress. It was recorded last week when we visited some of our UK-collaborators, here, Quay Pharma in north Wales, that recently manufactured new tablets for us for use in clinical trials!


Please, find the link to the video (in English) here

(02-March-2022)
Pila Pharma Press releases
PILA PHARMA AB – VD Dorte X. Gram ökar sitt innehav
Läs pressmeddelandet (in Swedish) här

 

PHARMA AB – CEO Dorte X. Gram increases share holding
Read the press release (in English) here

(25-February-2022)

PILA PHARMA bokslutskommuniké för 1 januari – 31 december 2021
Läs rapporten PDF (in Swedish) här

(18-February-2022)
Pila Pharma Press releases
PILA PHARMA bokslutskommuniké för 1 januari – 31 december 2021
Läs pressmeddelandet (in Swedish) här

 

PILA PHARMA publishes year-end report January 1 – December 31, 2021
Read the press release (in English) here

(18-February-2022)
Halsa Forskning Cover
Last week, our CEO Dorte X. Gram appeared in this issue of Hälsa & Forskning distributed with Svenska Dagbladet.
Please, read the article (in Swedish) here
(07-February-2022)
Pila Pharma Press releases

PILA PHARMA AB tillkännager milstolpe avseende API-produktion samt ändringar i organisationen
Läs pressmeddelandet (in Swedish) här

 

PILA PHARMA AB, announces API manufacturing milestone achieved and changes to organisation
Read the press release (in English) here

(04-February-2022)
Happy New Year! We’re back and looking toward an eventful 2022! 😃 
Biostock has written a small summary of us and our milestones for the coming year.
Find the links below! 😃
(SWE) here
(ENG) here
(19-January-2022)
On Friday our CEO Dorte X. Gram went for a film and photo shoot here at Malmö Live Konserthus
We can’t yet disclose what for so stay tuned 🤗
(17-January-2022)
Redeye this morning published their analysis of our business case.
Please, have a look if you need guidance on assessing our risks and the overall (investment) potential (in English) here
(17-December-2021)
Last pitch of the year was done yesterday our CEO Dorte X. Gram at Redeye
Please, find the link to the video (in Swedish) here
(17-December-2021)
Earlier today, our CEO Dorte X. Gram was interviewed by Aktier.
We thank for the invitation and many good questions!
Please, find interview in Swedish (start at time 4:19) here
(10-December-2021)
Please, check out this PILA PHARMA ’hisspitch’ that Aktiespararna made last week when our CEO Dorte X. Gram was in Stockholm.
Please, find the link to the video (in English) here
(10-December-2021)
Dr. Julius, yesterday, gave his Nobel prize lecture on the discovery of ’the chili receptor’ TRPV1 and its role in thermo-sensation and pain. Our diabetes drug candidate is a TRPV1-antagonist.
Please, find the link to the video (in English) here
(08-December-2021)
In case you missed it, our CEO’s presentation from today’s event at Aktiespararna is now online
Please, find the link to our CEOs presentation (in English) here
(02-December-2021)
Back To Top
Search